The study, "Medicine Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014," found that total dollars spent on medications in the country rose 13.1%, up from a 3.2% increase in 2013.
Drug spending in the United States last year was one for the record books. Pharmacists filled a record 4.3 billion prescriptions in 2014 that cost nearly $374 billion, according to a new report issued by the IMS Institute for Healthcare Informatics.
“The 13.1% increase in drug spending in 2014 was mainly driven by two things: the availability of new hepatitis C [HCV] treatments and very few products losing patent protection,” said Murray Aitken, IMS Health senior vice president and the executive director of the IMS Institute for Healthcare Informatics. “Sovaldi [sofosbuvir; Gilead] was the biggest drug launch in history.
“As for patent protection, the health system saves money when drugs move from branded products to generics. Typically, there has been a savings of between 15 [billion] and 30 billion a year due to patent expiries. But in 2014, that figure was only $12 billion,” he said.
Read the complete article on PainMedicineNews: http://bit.ly/1EUuScq
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More